BioMedNewsBreaks — Adageis at Forefront of Shift to Value-Based Care

Adageis is structured to support providers during a transformation of the U.S. healthcare system, shifting from fee-for-service models to value-based care. The company’s unique offering of tools and solutions simplify the necessary moves, including AI-driven analytics and patient-focused care solutions. “This transition prioritizes quality outcomes over service volume but requires a dramatic overhaul of infrastructure, culture and operations. Adageis, a forward-thinking healthcare technology company, is at the forefront of this shift, with its focus on revolutionizing patient care through innovative value-based solutions,” reads a recent article. “Adageis has all the tools needed to support providers during this transformation. Its ProActive Care Platform uses AI-driven predictive analytics to help healthcare organizations optimize care delivery and improve reimbursement under value-based contracts.”

To view the full article, visit https://ibn.fm/Df8IC

About Adageis
Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector. For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection

HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system,…

2 days ago

BioMedNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) to Deploy Fingerprint Drug Testing System Across MWS Sites in Australia

Intelligent Bio Solutions (NASDAQ: INBS) announced that Managed Waste Service (MWS), a leading Australian waste…

4 days ago

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Secures Two New Patents Advancing 3D ECG and Cardiac Monitoring Technology 

HeartBeam (NASDAQ: BEAT), announced the issuance of two new U.S. patents that strengthen its intellectual…

4 days ago

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Advances Aversa Fentanyl with Kindeva to Commercial Manufacturing Scale

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the successful commercial manufacturing…

4 days ago

BioMedNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) CEO Highlights Fingerprint Drug Testing on BioMedWire Podcast

Intelligent Bio Solutions (NASDAQ: INBS) CEO Harry Simeonidis joined the latest episode of The BioMedWire…

5 days ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Join Forces to Advance Remote Cardiac Monitoring

HeartBeam to integrate AccurECG(TM), AccurKardia’s FDA-cleared ECG analysis software Collaboration enhances HeartBeam’s commercial offering with…

5 days ago